Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 1
2005 1
2006 1
2007 1
2012 3
2013 1
2017 2
2021 2
2022 1
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Tailoring neoadjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations.
Elghazaly H, Azim HA, Rugo HS, Cameron D, Swain SM, Curigliano G, Harbeck N, Tripathy D, Arun B, Aapro M, Piccart M, Cardoso F, Gligorov J, Elghazawy H, El Saghir NS, Penault-Llorca F, Perez EA, Poortmans P, Abdelaziz H, El-Zawahry HM, Kassem L, Sabry M, Viale G, Al-Sukhun S, Gado N, Leung JWT, Ezz Elarab L, Cardoso MJ, Abdel Karim K, Foheidi M, Elmaadawy MM, Conte P, Selim ASM, Kandil A, Kamal RM, Paltuev RM, Guarneri V, Abulkhair O, Zakaria O, Golshan M, Orecchia R, ElMahdy M, Abdel-Aziz AM, Eldin NB. Elghazaly H, et al. Among authors: el zawahry hm. Cancer. 2024 Oct 1;130(19):3251-3271. doi: 10.1002/cncr.35389. Epub 2024 Jul 10. Cancer. 2024. PMID: 38985794
Novel therapeutic strategies in the treatment of triple-negative breast cancer.
Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, Lim B, Mellas N, Ueno NT, Fouad TM. Oualla K, et al. Among authors: el zawahry hm. Ther Adv Med Oncol. 2017 Jul;9(7):493-511. doi: 10.1177/1758834017711380. Epub 2017 Jun 13. Ther Adv Med Oncol. 2017. PMID: 28717401 Free PMC article. Review.
The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts.
Bazarbashi S, El Zawahry HM, Owaidah T, AlBader MA, Warsi A, Marashi M, Dawoud E, Jaafar H, Sholkamy SM, Haddad F, Cohen AT. Bazarbashi S, et al. Among authors: el zawahry hm. J Blood Med. 2024 Apr 25;15:171-189. doi: 10.2147/JBM.S411520. eCollection 2024. J Blood Med. 2024. PMID: 38686358 Free PMC article. Review.
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Gligorov J, et al. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. Eur J Cancer. 2017. PMID: 28625777 Clinical Trial.
Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.
Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA, Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip CH, Ghosn M, Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, Gligorov J, Gulluoglu BM, Abdel Aziz H, Frolova M, Sabry M, Balch CM, Orecchia R, El-Zawahry HM, Al-Sukhun S, Abdel Karim K, Kandil A, Paltuev RM, Foheidi M, El-Shinawi M, ElMahdy M, Abulkhair O, Yang W, Aref AT, Bakkach J, Bahie Eldin N, Elghazawy H. Elghazaly H, et al. Among authors: el zawahry hm. Cancers (Basel). 2021 May 8;13(9):2262. doi: 10.3390/cancers13092262. Cancers (Basel). 2021. PMID: 34066769 Free PMC article.
The first BGICC consensus and recommendations for breast cancer awareness, early detection and risk reduction in low- and middle-income countries and the MENA region.
Elghazaly H, Aref AT, Anderson BO, Arun B, Yip CH, Abdelaziz H, Ghosn M, Al-Foheidi M, Cardenosa G, Leung JWT, Gado N, Balch CM, Sabry M, Ezz Elarab L, Giuliano AE, El-Zawahry HM, Abdel Karim K, Nasr A, Maki H, Chung H, Saadeddin A, Abdelwahab MM, Al Tahan FM, Chalabi N, Frolova M, Kamal RM, Shehata MA, Bahie Eldin N, Elghazawy H. Elghazaly H, et al. Among authors: el zawahry hm. Int J Cancer. 2021 Aug 1;149(3):505-513. doi: 10.1002/ijc.33506. Epub 2021 Feb 21. Int J Cancer. 2021. PMID: 33559295
Clinical Significance of ALK-1 Gene Abnormalities in Diffuse Large Cell Lymphoma.
Korashy L, El-Zawahry H, Abdou S, Shahin D, Sherif F, Farrag W, Abdel-Khalik O, Salem H, El-Sebaaie A. Korashy L, et al. Among authors: el zawahry h. Clin Med Insights Oncol. 2012;6:395-405. doi: 10.4137/CMO.S9920. Epub 2012 Nov 26. Clin Med Insights Oncol. 2012. PMID: 23239932 Free PMC article.
A phase II study of epirubicin in breast cancer.
el Mawla NG, Hamza MR, el Khodari A, Khaled H, Gaafar R, el Zawahry H, abdel Wareth A, Dardir MD, Habboubi N. el Mawla NG, et al. Among authors: el zawahry h. Anticancer Drugs. 1991 Aug;2(4):371-4. doi: 10.1097/00001813-199108000-00006. Anticancer Drugs. 1991. PMID: 1797193 Clinical Trial.
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C; TRIO/BCIRG 001 investigators. Mackey JR, et al. Lancet Oncol. 2013 Jan;14(1):72-80. doi: 10.1016/S1470-2045(12)70525-9. Epub 2012 Dec 12. Lancet Oncol. 2013. PMID: 23246022 Clinical Trial.
15 results